Enzon Shareholders Steal the Show

On Tuesday, Enzon Pharmaceuticals (Nasdaq: ENZN  ) wanted to trumpet its first-ever data presentations at a major medical conference. Too bad an activist investor chose that same day to prod Enzon to consider more strategic alternatives.

Enzon announced earlier this month that it would split its development-stage biotech pipeline assets from its specialty-pharma marketed drugs, in hopes of realizing a fuller value for the company. The company joins other drugmakers, including PDL BioPharma (Nasdaq: PDLI  ) and Nabi Biopharmaceuticals (Nasdaq: NABI  ) , which have recently spun off, potentially sold, or announced plans to spin off their different businesses.

Enzon's move to separate its myriad business lines followed calls from activist investors such as DellaCamera Capital Management and Carl Icahn for the company to better showcase its potentially undervalued assets. As DellaCamera made clear on Tuesday in a press release and 13D filing, it's displeased with Enzon's plan to spin off only its biotech business. DellaCamera thinks Enzon could better maximize its value by trimming its executives' salaries and shopping its assets to "strategic buyers."

DellaCamera currently holds 5.9% of all outstanding shares of Enzon. Assuming Icahn is on its side, shareholders controlling at least 12.7% of Enzon's shares will be agitating for more changes at the company. While activist investors like DellaCamera and Icahn don't always get their way, they can definitely make things interesting for a company. We'll soon see just how interesting things get for Enzon.

Further Foolishness about pesky investors:

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a 30-day free trial subscription.

Fool contributor Brian Lawler owns shares of PDL but no other company mentioned in this article. The Fool has an A+ disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 650857, ~/Articles/ArticleHandler.aspx, 10/28/2016 8:35:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/10/2016 3:59 PM
ENZN.DL $0.40 Down +0.00 -1.00%
Enzon Pharmaceutic… CAPS Rating: ***
NABI.DL $10.80 Down +0.00 +0.00%
Nabi Biopharmaceut… CAPS Rating: *****
PDLI $3.33 Down +0.00 +0.00%
PDL BioPharma CAPS Rating: ***